Podcasts about PD

What if the key to classroom behavior isn't discipline—but cognitive clarity? In this mind-shifting episode of Aspire to Lead, Mitch Weathers, author of Executive Functions for Every Classroom and creator of Organized Binder, joins us to unpack the real impact of cognitive overload and working memory on student behavior. We explore how executive functioning isn't just a set of skills—it's the backbone of a thriving learning environment. Mitch breaks down practical strategies that help educators reduce chaos, boost student focus, and build routines that make better behavior the natural outcome of smarter systems. If you're ready to ditch reactionary discipline and lean into structure, mindset, and clarity—this episode is your blueprint. About Mitch Weathers: Mitch became a gifted teacher because he was a mediocre student. Mitch rarely felt comfortable in the classroom. In fact, it took him 7 years for him to graduate from college. Choosing to become a teacher, Mitch was fortunate enough to experience school as if it was happening all around him. He was unsure how to jump into his learning with confidence. There is a loneliness to experiencing your education as a passive object as opposed to an active subject. From the moment he entered the classroom Mitch relied on his personal experiences as a learner. He recognized that what we teach, the content or curriculum, is secondary. We must first lay the foundation for learning before we can get to teaching. Mitch designed Organized Binder to empower teachers with a simple but research-backed strategy to teach students executive functioning skills while protecting the time needed for content instruction. The secret is found in establishing a predictable learning routine that serves to foster safer learning spaces. When students get practice with executive functions by virtue we set them up for success. Follow Mitch Weathers: Website: www.organizedbinder.com Twitter: https://twitter.com/organizedbinder Instagram: https://www.instagram.com/organizedbinder/ Facebook: https://www.facebook.com/organizedbinder Linkedin: https://www.linkedin.com/in/mitchweathers/ Vimeo OB showcase: https://vimeo.com/showcase/8775721 — Tired of the same old PD that leaves you inspired but still stuck? What if one night could shift everything? VIBEEDU: Educators Defining Unity A one-night revolution — no fluff, no empty inspiration. Just bold ideas, real strategies, and lasting change. August 1st, 2025 | 5–9 PM | ARTIC, Anaheim, CA Join authors, educational leaders, neuropsychologists, and advocates for powerful conversations that challenge the status quo. Designed for district leaders, principals, teachers, and parents of neurodivergent students ready to lead with intention and take action. Learn More and Register HERE: https://www.teachinginsideout.com/vibe-edu — Magic Mind If you are a long time listener, an ASPIRE Leader, You know I only work with brands that I believe in myself and I integrate in my everyday life, so I'm super happy to talk to you guys about Magic Mind! I started...

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Throwback Thursday! Title: Support(ing) Students Affected by Trauma featuring Anthony SwannOriginally Released On: 7-2-2021This week, we're revisiting one of our timeless episodes from Leading Out The Woods! In this episode:✅ Anthony shares how he supports students in his classroom related to his personal experiences with trauma.✅ Anthony gives strategies that could benefit other educators working with a variety of students.Whether you're hearing it for the first time or revisiting a classic, this conversation is packed with insights that still resonate today.

In this final episode of our June Summer Strategy series, we're turning the spotlight back on YOU—your growth, your leadership, and your mindset. Summer isn't just a time to rest (though that's definitely important!)—it's also the perfect opportunity for intentional learning that fills your cup instead of draining it.Whether you want to build stronger systems, lead your para team more effectively, or learn how to better support your autistic learners, this episode reminds you that professional development can be empowering, not overwhelming.

Music education is an important part of primary school. It's got a range of benefits, of course, not only for students' music learning, but for improving their capacity as a learner more broadly, and there are benefits for their wellbeing too. In Episode 101 of The Research Files we're joined by Dr Rebecca Taylor, a Senior Research Fellow at the Australian Council for Educational Research. We're going to be exploring survey data from 2 reports into music teaching and music education in primary schools – they're all about the ‘what', ‘when', and ‘how' music learning is delivered. Our chat certainly provides some food for thought in terms of what you're doing in your own practice and maybe the supports that you need; if you're a school leader, maybe what expertise exists within the staff and what their PD needs are. Host: Jo Earp Guest: Dr Rebecca Taylor

Welcome back to School Counseling Simplified! We're continuing our special Summer Summit speaker series, and today I'm joined by an incredible pair: Monique and Patti, two clinical social workers and certified play therapists who specialize in attachment and child development. They recently spoke at Summer Summit about a topic that's essential for every educator and school counselor: Attachment Theory in the Classroom. If you missed Summer Summit, it's not too late. When you join IMPACT, my monthly school counselor membership, you'll gain access to all of the Summer Summit recordings and PD hours—including Monique and Patti's impactful session. Monique Gougeon, MSW, RSW, CPTS, CTPS has a Masters Degree in Clinical Social Work and is a Certified Child Therapist and Play Therapist Supervisor with the Canadian Association of Play Therapy. Monique is certified as Theraplay Practitioner, Trainer and Supervisor with Theraplay Canada. She is also certified in Circle of Security Individual and Group models and is a Certified EMDR practitioner, specializing in Child and adolescent treatment. Monique has extensive experience working with children and families in community agencies and has worked for 20+ years in the field of children's therapy. She is the owner of Alloway Therapy Services in Winnipeg, Manitoba, Canada, where she practices alongside her talented colleagues. Monique has special interests in supporting children who have experienced loss, developmental trauma, and attachment disruption. She regularly facilitates training and presentations for caregivers and professionals regarding child trauma and attachment disruption.  Patti has a Masters in Social Work and has been a social worker for over 30 years. She has worked with children in women's shelter's, family violence programs, schools and spent 12 years in private practice. She is a Certified Play therapist with The Canadian Association of Play Therapy. She enjoys providing training for educators in the area of developmental trauma in the classroom and is currently a school social worker in the Winnipeg School Division in Winnipeg, Canada. About a year ago Patti decided she would try her hand at creating resources for school counselors and opened a TPT shop. A major learning curve, but an exciting new adventure.    In This Episode: Monique and Patti dive into how we can apply attachment theory and the Circle of Security framework within the classroom and school counseling settings. We talk about: Why attachment-based practices aren't just for “high-need” students but benefit all kids How the Circle of Security model, originally created for caregivers, can be adapted for educators and school counselors Ways to support students as they explore their world while also providing a secure base Shifting from behavior-based approaches to relational ones How restorative practices can preserve relationships, rather than relying on punitive systems A framework to help counselors and teachers feel more confident and less burned out They also share the PACE model—a mindset for working with children: Playful Accepting Curious Empathic By embodying these qualities, educators can create safer, more nurturing environments for all students.   A Day in the Life (Patti): Patti shares a glimpse into her workweek, which includes: Direct client work 3 days per week, supporting children and caregivers Teaching play therapy curriculum through Therapy Canada Institute Providing supervision and training in therapeutic models: her work centers around integrating play, attachment, and trauma-informed practices to support school-aged children. Want to Learn More? Monique and Patti are hosting a 2-day training on August 18th and 19th. This is a fantastic opportunity to dive deeper into Circle of Security and attachment-informed practices for schools. Pre-register now to save your spot!   Don't miss out! Want access to this session and more? Join the IMPACT membership to get all Summer Summit replays, monthly PD trainings, downloadable resources, and a community of fellow school counselors.   Resources Mentioned:   Join IMPACT Pre-Registration for 3Rs: Attachment in the Classroom August 18 &19, 2025   Connect with Rachel: TpT Store Blog Instagram Facebook Page Facebook Group Pinterest Youtube Connect with Patti: Teachers Pay Teachers Email Patti: ps@pattisutherland.ca PS Counseling Matters Newsletter Connect with Monique: Email Monique: monique@allowaytherapy.com   More About School Counseling Simplified: School Counseling Simplified is a podcast offering easy to implement strategies for busy school counselors. The host, Rachel Davis from Bright Futures Counseling, shares tips and tricks she has learned from her years of experience as a school counselor both in the US and at an international school in Costa Rica. You can listen to School Counseling Simplified on Apple Podcasts, Spotify, Google Podcasts, and more!    

In this episode of The Principal's Handbook, Barb dives into how principals can create a personal summer professional development (PD) plan. It's time to reflect on your leadership growth, set intentional goals for improvement, and find the right resources to sharpen your skills for the upcoming school year.Key Points:Reflect on the past school year: Celebrate successes and identify areas for growth.Find the right resources: Podcasts, books, online courses, or coaching can help you develop in areas like communication, behavior management, and confidence.Set actionable goals: Visualize success and break goals into manageable tasks with a clear timeline.Tune in for a roadmap to help you grow as a leader this summer and come back ready to tackle next school year with confidence!FREE DOWNLOADS*The Principal's Email DetoxDecisive Leadership- Free WorkshopPrincipal Checklist to Disconnect From SchoolBehavior Blueprint for PrincipalsThe Principal's Power Hour Blueprint*RESOURCES FOR PRINCIPALS*Transform Your Time: 60 Day Action Plan for PrincipalsLeadership by Design: The Principal's Custom Habit SystemThe Principal's Overwhelm Toolkit*SOCIAL MEDIA*Barb Flowers, Ph.D- LinkedinDrBarbFlowers- Instagramthe8to4principal- TikTok

Send us a textHit the restart button with Celine as she welcomes a dynamic coaching team, Ben and "Katie Mac" from Career Campuses. Discover how they're revolutionizing professional development with their "Learnapalooza" event, injecting fun and growth mindset into their unique career tech environment.From welding to cosmetology, learn how these coaches build vital relationships by diving into teachers' diverse worlds, even getting their hands dirty (or polished!). They'll share practical tips on co-teaching models, team collaboration, and the power of knowing your "why" to drive impactful change. Plus, get a peek into their playful approach to PD, including music-themed sessions and competitive "Tech Madness."Tune in to recharge your coaching batteries and leave feeling less alone on your coaching island, equipped with fresh insights and a renewed sense of community!

Medical appointments can feel overwhelming – there may be many questions on your mind and not enough time to address everything with your doctor. Preparing a list of questions and concerns ahead of time can help you focus on what matters most to you and ensure you're actively advocating for your care. To support this process, the Parkinson's Foundation created a worksheet that offers a step-by-step guide for identifying and prioritizing your top concerns.  Advocating for yourself during appointments can be challenging, and at times, uncomfortable. Speaking up is essential to make sure your top needs are heard and addressed. In this episode, we speak with Dr. Taylor Rush, a Health Psychologist and director of Behavioral Services and Interdisciplinary Programs at the Cleveland Clinic in Ohio. She shares her recommendations for how to prepare before, during, and after a visit with your Parkinson's doctor, take a proactive role in managing your care, and access helpful resources to support you throughout your Parkinson's journey. Follow and rate us on your favorite podcast platform to be notified when there's a new episode! Let us know what other topics you would like us to cover by visiting parkinson.org/feedback.

“Every mammal on this planet, instinctively develops a natural equilibrium with the surrounding environment. But you humans do not. You move to an area and you multiply- and multiply until every natural resource is consumed. The only way you can survive is to spread to another area.” – The Matrix Hugo Weaving's Mr. Smith lectures Lawrence Fishburne's Morpheus in The Matrix on humanity's fatal flaw. While history may paint a negative picture of our efforts, the future looks bright. That future is sustainability, a paradigm shift that promises to reshape our relationship with the environment and the resources we consume. This vision of sustainability is not just about preserving nature; it's about creating a healthier, more resilient world for future generations. The components of sustainability in the tech world include energy efficiency, waste reduction, water conservation, reducing greenhouse gas emissions, sustainable product design, and employee engagement. Energy efficiency: companies can optimize manufacturing processes to reduce energy consumption and developing products that are more energy-efficient to cut down operational costs and reduce the impact on the environmental impact. Waste reduction: comprehensive recycling programs, reducing material usage, and improving manufacturing processes, companies can minimize the environmental footprint of their operations and products. Water conservation: Implementing measures to recycle and reuse water to a point where every drop could be recaptured and reused. Reducing greenhouse gas emissions: This is where the bulk of the efforts can yield real benefits to lower carbon footprints, and reduce/reuse/recycle with ambitious goals of net-zero by 2040. Sustainable product design: there is a fine balance between creating energy-efficient and environmentally friendly products that meet regulatory standards and customer expectations, while also generating a reasonable rate of return for stakeholders. Employee engagement: Encouraging employees to participate in sustainability programs and providing training and resources to support those practices keep the environment front of mind while also pursuing the business of business. One company that exemplifies these principles is Microchip Technology. Their commitment to sustainability is evident in their comprehensive approach, known as Microchip 360° Sustainability. This includes energy efficiency, waste reduction, water conservation, and reducing greenhouse gas emissions. Their products, such as the PD77728 and PD-70228 ICs, are designed with the lowest power consumption in mind, and their packaging is 100% recyclable, PVC-free, halogen-free, and compliant with ROHS and REACH standards. The GS series of midspans takes this even further with improvements in key areas. Microchip's dedication to sustainability has not gone unnoticed. Forbes recently named them a Net Zero Leader, ranking them #6 on the list. This recognition highlights their leadership in reducing greenhouse gas emissions and promoting sustainable practices. Companies like Microchip are taking real, tangible actions to protect the environment, conserve resources, and minimize waste.   How can Microchip Technology show real leadership in driving sustainability for future generations?   Links from the episode: Microchip's Commitment to Sustainability: Operational Excellence and Innovative Customer Solutions | Microchip Technology microchip.com/poe   Guest: Alan Zwiren

커튼콜 270회에서는 장안의 화제가 된 '춤추는 마에스트로' 백윤학 씨를 만나봅니다. 영남대학교 교수이자 서울 페스타 필하모닉 오케스트라 지휘를 맡고 있는 백윤학 씨는 모니터링을 위해 촬영한 직캠 영상이 화제가 되면서 '춤추는 지휘자'로 유명해졌는데요. 화제의 직캠 영상과 단원들 이야기를 통해 춤추는 지휘의 매력을 집중탐구합니다. '앙코르 오마카세'는 어떻게 선보이는지, 서울대 공대생이었던 그는 왜 음악을 하게 되었는지, 미국에서 지휘와 오페라 코치 과정을 공부한 과정은 어땠는지, 춤 말고도 다채로운 이야기 나눴습니다. 그가 지휘를 맡은 올해 줄라이 페스티벌 개막작, 스트라빈스키 '병사의 이야기'도 예습해 봅니다. ♬ 춤추는 지휘자 - Russian Dance Trepak vs aladdin ♬ 스브스뉴스 - 지휘자인데 직캠이 있다고 직업 만족도 최상★ 춤추는 지휘자 ♬ SBS 영상취재 - 지휘 마스터 클래스 영상 출처 제공 : 서울 페스타 필하모닉 오케스트라, 스브스 뉴스, SBS 영상취재 유튜브 재생목록 '김수현 문화전문기자의 커튼콜'을 추가해 보세요. https://han.gl/3YIq8 진행: SBS 김수현 문화전문기자, 이병희 아나운서 l 출연: 지휘자 백윤학 l 글·편집 : 김은혜 PD

I'm a Human Sustainability Consultant with a deep background in education, emotional engagement, and systems transformation. My work centers on helping schools, districts, and organizations create emotionally sustainable environments where people feel seen, supported, and empowered to lead.My professional path began as an elementary teacher with a passion for technology. Over time, I served as a Technology Integrator, Director of Innovation and Technology, and later as a consultant focused on instructional strategy and educator support. While my roles evolved, one thing remained constant: a commitment to understanding how systems affect the people inside them.​After facing burnout myself at a time when there were no pathways for healing or even permission to talk about it, I shifted my focus toward mental health advocacy and policy change. For many years, I've worked at the intersection of instructional innovation and emotional well-being. Though I'm not a therapist or counselor, I've always been clear about my role: I am an advocate, strategist, and systems thinker, committed to improving the human experience of those working in schools and educational organizations.​As a consultant, I provide strategic guidance and professional learning for both private sector organizations and educational institutions. My focus is on building emotionally sustainable systems that reduce burnout, restore engagement, and improve long-term performance across teams. I specialize in areas such as employee well-being, emotionally intelligent leadership, systems-level change, and culture transformation. I also support organizations in aligning their internal practices with people-first values, ensuring that policy, communication, and culture all contribute to a healthier and more effective workplace.​In addition to consulting, I am a speaker, facilitator, and author whose work has centered on workplace mental health, employee engagement, and the conditions needed to support innovative thinking. I design and deliver high-impact learning experiences that are practical, reflective, and transformative whether for business leaders, education professionals, or hybrid teams. I believe that when organizations truly invest in their people, they don't just improve retention and performance—they build cultures where people can grow and stay.​At home, you'll usually find me with my family, out with my horses, or having in-depth conversations with my dogs over coffee. I've devoted my life to creating spaces where people can reconnect to their sense of purpose. Seeing others find clarity, fulfillment, and renewed energy in their work is what keeps me doing this work every day.Education BackgroundBachelor's Degree: Elementary EducationMaster's Degree: Information and Communication TechnologiesMaster's Degree: Educational Leadership (Principal and Director of Instruction Certifications)Doctorate: Educational Sustainability (in progress)Certification: Diversity, Equity, and Inclusion (in progress)Certification: Alternative Education ______________________________________________________________________ The Edupreneur: Your Blueprint To Jumpstart And Scale Your Education BusinessYou've spent years in the classroom, leading PD, designing curriculum, and transforming how students learn. Now, it's time to leverage that experience and build something for yourself. The Edupreneur isn't just another book—it's the playbook for educators who want to take their knowledge beyond the school walls and into a thriving business.I wrote this book because I've been where you are. I know what it's like to have the skills, the passion, and the drive but not know where to start. I break it all down—the mindset shifts, the business models, the pricing strategies, and the branding moves that will help you position yourself as a leader in this space.Inside, you'll learn how to:✅ Turn your expertise into income streams—without feeling like a sellout✅ Build a personal brand that commands respect (and top dollar)✅ Market your work in a way that feels natural and impactful✅ Navigate the business side of edupreneurship, from pricing to partnershipsWhether you want to consult, create courses, write books, or launch a podcast, this book will help you get there. Stop waiting for permission. Start building your own table.

Lead Pastor Don Jackson (PD) continues the Biblical Worldview' series in the book of Romans and in the book of Isaiah. PD uses various scripture passages to paint a picture of the Glory of God. Once we understand more about God's glory, it is easier to entrust our lives to Him. Online Message Notes

What does it mean to lead like a BISON? In this energizing episode, Kim Gameroz joins me to talk about her new book Becoming the Bison, her powerful new podcast Unleashing the Bison, and the highly anticipated VIBE Edu event on August 1st—where I'm honored to be speaking! Together, we explore how school leaders can launch Social Emotional Learning the right way, avoiding the culture-killing mistakes that make it feel like “just one more thing” for teachers. Kim shares how her team partners with schools and districts to reduce student discipline issues and improve learning outcomes. She also reveals how her B.I.S.O.N. community has become a beacon of hope and resilience for educators nationwide. This conversation is all about practical strategies, bold leadership, and the kind of community that makes transformation possible. Tune in and get ready to charge forward with courage, purpose, and a herd by your side! About Kim Gameroz Kim Gameroz, M.Ed., is a change agent and founder of Teaching Inside Out, revolutionizing classrooms through a systematic approach to teaching social and emotional skills. With over 15 years of experience coaching, training, and mentoring educators, students, and families globally, Kim has spoken at numerous conferences, consults for school districts, serves on SEL panels, and contributes to various publications and podcasts. Through Teaching Inside Out, as well as her second company, SELebrate Good Times, she has created a supportive community for heart-centered educators nationwide where she is committed to making teachers feel seen, valued, and SELebrated at her events and teacher retreats. Kim's upcoming book, "Becoming The Bison," is set to be published in 2025.   She currently resides in Dallas, Texas with her husband, Shaun, and son, Wyatt, and is looking forward to spreading her knowledge of SEL and best practices in teaching even further to schools, districts, and homes around the world.  Visit SELebrate Good Times to learn more about the teacher community that is changing lives all over the country, and her annual National SELebration: The Bloom! Follow Kim Gameroz: Website: SELebrateGoodTimes.com and TeachingInsideOut.com Instagram: @SELebrateGoodTimes and Teaching_Inside_Out LinkedIn: https://www.linkedin.com/in/kim-gameroz-18144b1b0/  Private Facebook Group: Becoming the B.I.S.O.N. Tired of the same old PD that leaves you inspired but still stuck?

This summer we'll be interviewing a handful of interesting people who are living with Parkinson's. First up: the novelist Linda Grant. Linda started life as a journalist before becoming acclaimed fiction writer who won the Women's Prize in 2000 for her novel When I Lived in Modern Times, and was shortlisted for the Booker Prize in 2008 for The Clothes on Their Backs. Here, she talks for the first time about her Parkinson's diagnosis, how it has impacted her writing, and how she plans to become (maybe) the first writer to bring to life a protagonist living with PD.Don't forget to sign the Parky Charter petition by going to ParkyPetition.com!Sponsored by Boardwave, who support Cure Parkinson's.Presented by Rory Cellan-Jones, Gillian Lacey-Solymar, Mark Mardell, Paul Mayhew-Archer, Sir Nicholas Mostyn and Jeremy Paxman.Produced and edited by Nick Hilton for Podot.Sound mixing by Ewan Cameron.Music by Alex Stobbs. Hosted on Acast. See acast.com/privacy for more information.

BUFFALO, NY – June 20, 2025 – A new #review was #published in Volume 16 of Oncotarget on June 10, 2025, titled “Beyond DNA damage response: Immunomodulatory attributes of CHEK2 in solid tumors.” In this paper, led by first author Helen Qian and corresponding author Crismita Dmello from Northwestern University Feinberg School of Medicine, researchers compiled growing evidence that the CHEK2 gene, long known for its role in repairing DNA damage, may also influence how tumors respond to immunotherapy. Their analysis suggests that problems in CHEK2 function might make cancer cells more vulnerable to immune system attacks, highlighting a new opportunity to improve treatment outcomes in solid tumors. Immune checkpoint inhibitors (ICIs) have transformed cancer treatment; however, they are effective in only a subset of patients. This review suggests that tumors with reduced CHEK2 activity may accumulate more mutations that produce signals the immune system can recognize. These signals, known as neoantigens, help immune cells identify and destroy cancer cells more effectively. The review connects this process not only to CHEK2's established role in the DNA damage response but also to a newly proposed function in shaping the immune environment of tumors. CHEK2 normally helps maintain genomic stability by enabling precise DNA repair. When this function is lost, cells rely on more error-prone repair methods, leading to additional mutations. These mutations can increase tumor mutational burden, which has been linked to better outcomes with immunotherapy. Beyond DNA repair, the review highlights a second mechanism: activation of the cGAS-STING pathway. This pathway detects fragments of damaged DNA and triggers inflammation that attracts immune cells to the tumor. The authors highlight studies where CHEK2-deficient tumors responded better to PD-1 inhibitors, a common type of immune checkpoint inhibitor. In both lab models and early-stage clinical settings, CHEK2 loss was associated with increased infiltration of CD8+ T cells—immune cells essential for attacking cancer cells. In cancers such as glioblastoma and renal cell carcinoma, which are typically resistant to immunotherapy, reduced CHEK2 expression was linked with more favorable immune activity and higher expression of interferon-related genes. The compiled evidence points to CHEK2 as a potential biomarker for identifying patients likely to respond to immunotherapy. In addition, combining CHEK2 inhibitors with existing immunotherapies may enhance anti-tumor effects, particularly in cancers with limited treatment options. The review notes that some clinical trials using the CHEK1/2 inhibitor prexasertib alongside immune checkpoint therapies have already shown promising early results. “The initial results from this Phase I clinical trial support the immunomodulatory role of CHEK2 expression and even suggest CHEK2 potentiates immunosuppression.” Although more research is needed to confirm these mechanisms and improve treatment approaches, this review underscores the expanding role of DNA repair genes like CHEK2—not only in maintaining genome integrity but also in helping the immune system fight cancer. DOI - https://doi.org/10.18632/oncotarget.28740 Correspondence to - Crismita Dmello - stellacpak@outlook.com Video short - https://www.youtube.com/watch?v=C26pEBc0itk Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Send us a text

In apertura la lettura critica dei quotidiani di oggi in edicola con Paolo Mieli.Sabato a Roma doppio corteo per la pace e contro il piano di riarmo. Il corteo e la piattaforma che lo sostiene hanno però creato divisioni nella sinistra italiana. Alcuni gruppi e soggetti politici mostrano divergenze sulle modalità e sui contenuti della protesta, in particolare riguardo al rapporto con la Nato, la cooperazione militare con Israele, e le strategie di pace e disarmo da adottare. Per parlarne ospitiamo Angelo Bonelli, deputato e co-portavoce di Europa Verde e Pina Picierno, vicepresidente del Parlamento europeo ed eurodeputata del Pd.

Diet culture has taught us that eating less is always the answer—but what happens when your coach tells you to eat MORE?That's exactly the conversation Coach Mia had with her client, Agness. Even when you think you're doing everything right, chronic under-eating can sabotage your progress. The constant message to "shrink your food to shrink your body" creates a cycle of over-restriction that works against your goals.In this episode, Mia shares how she helped Agness reach her goals by increasing her calories and teaching her to fuel her body without fear. Eating more might be the missing piece in your own health journey.If YOU'RE ready to make real, sustainable change in your life, jump on a free call with us - ⁠https://physiquedevelopment.typeform.com/to/ToP9TYLEAs always, it is our goal not only to supply you, the listener, with valuable insights on the topics or questions but also to plant some seeds for further research and thought. Be sure to like and subscribe and leave us a review if you loved this episode!Connect with Coach Mia & Team PD:Coach Mia: https://www.instagram.com/mia.fergusonPhysique Development: https://www.instagram.com/physiquedevelopment_Physique Development Podcast: https://www.instagram.com/physiquedevelopmentpodcastInquire to work with Team PD: https://physiquedevelopment.typeform.com/to/ToP9TYLEHave questions or comments for us? Submit them here - https://forms.gle/AEu5vMKNLDfmc24M7Check out our FREE 4-Week Glute Program - https://bit.ly/podcastglutesAnd keep the gains rolling with 12 MORE weeks of glute growth (use code POD at checkout for $25 off!) - https://train.physiquedevelopment.com/workout-plans/963551Keep up to date with all things PD, get exclusive content, snag freebies, and more by joining our email list! - https://dedicated-artist-6006.ck.page/emailsignupInterested in the Physique Development Training Club App? Join here! - https://physiquedevelopment.appInquire to learn about nutrition-only coaching WITH exercise review - https://bit.ly/optimizeglutesGrab a band tee here! - https://shopphysiquedevelopment.comLooking to hire the last coach you'll ever need? Apply here - https://physiquedevelopment.typeform.com/to/ToP9TYLEInterested in competition prep? Apply here - https://physiquedevelopment.typeform.com/to/Ii2UNAFor more videos, articles, and information, head to - https://physiquedevelopment.comIf you would like to support Physique Development and this podcast, please head over to your favorite podcast app and leave us a rating and review! This goes a long way in supporting this podcast and helps us continue to bring high-quality, honest content to you in the form of a podcast. Thank you for listening and we will see you all next time!----Produced by: David Margittai | In Post MediaWebsite: https://www.inpostmedia.comEmail: david@inpostmedia.com© 2025, Physique Development LLC. All rights reserved.

Throwback Thursday! Diversity as Value-Added featuring Dr. Leighangela BradyOriginally Released On: 9-8-2023This week, we're revisiting one of our timeless episodes from Leading Out The Woods! In this episode:✅ Dr. Brady shares the work her team is doing in National School District to develop exceptionally prepared learners.✅ Dr. Brady gives tips on engaging all stakeholders in meaningful planning and strategic partnerships.Whether you're hearing it for the first time or revisiting a classic, this conversation is packed with insights that still resonate today.

Send us a textIn this episode, we unpack a big question: What's your vision for math classrooms? From years of visiting classrooms and leading professional development, our guest shares a powerful answer rooted in three values: joy, curiosity, and teacher sustainability. This isn't just an ideal—it's a framework leaders and teachers can work toward right now.

Let's be honest—most PD just doesn't get special ed. If you've ever sat through a training that had nothing to do with IEPs, visuals, or the beautiful chaos of your classroom… same.  That's why this week, we're ditching the fluff and diving into three totally free PD options made just for special ed teachers. Whether you're a seasoned pro or new to the scene, these resources are built to support your unique classroom, your time, and your sanity—no death-by-PowerPoint included. What You'll Learn: Where to find free, flexible PD that won't waste your time How to join a community that gets it Why this summer is the perfect time to prep without the pressure Where to get real talk from actual special ed teachers (no corporate speakers here!) Links and Resources Join the Special Ed Socials Facebook Group  Jump into the Summer Launchpad Challenge  Register for the FREE SPED Conference    Connect with Dawn   Find me on IG Find me on Tik Tok Etsy Shop TpT Store Subscribe Are you subscribed to my podcast? Trust me, you definitely want to do that so you don't miss a thing! Click here to subscribe in iTunes! Leave a Review If you are loving the podcast, I would be really grateful if you left me a review over on iTunes, too. Those reviews help other teachers find my podcast and I love hearing what you think about the podcast as well. Just click here to review, select “Ratings and Reviews” and “Write a Review” and let me know what part of the podcast you found to be the most helpful!

Life with Parkinson's disease (PD) is shaped by myriad factors, including sexual orientation and gender identity that shape access to care, lifestyle decisions and more. In this episode of The Michael J. Fox Foundation's Parkinson's Podcast, our expert panel shares their personal stories and discusses the ongoing research into the health concerns and needs of LGBTQ+ people living with PD. To connect with others for support and community, join the Parkinson's Buddy Network. https://parkinsonsbuddynetwork.michaeljfox.org/ Like our podcasts? Rate or review the show and share the series with your community. https://apple.co/3p02Jw0 The Foundation's landmark study, the Parkinson's Progression Markers Initiative, also known as PPMI, is recruiting volunteers. Join the study that's changing everything at michaeljfox.org/podcast-ppmi. Mentioned in this episode:The Foundation's landmark research study is exploring the connection between sense of smell and brain disease. People with and without Parkinson's can help by taking a free scratch-and-sniff test. Get yours at mysmelltest.org/request.

스포츠 타임라인 ‣ 선제골 허용 후 무득점… 울산, F조 첫 경기서 고전 ‣ 마이애미와 결별한 고우석, KBO 무대 복귀 가능성 제기 ‣ 토트넘 투어 동행 후 결정될 가능성… 손흥민 이적설 ‘유보' 상태 ‣ 파리올림픽 금메달리스트 도경동, 아시아 무대서도 압도 정PD와 김기자 ‣ 실전 감각 유지한 리베라토, 입국 직후 1군 데뷔 눈앞 ‣ 고우석 방출→KBO 리턴 가능성↑' LG, 갑자기 구원 왕국? ‣ KIA, 가을야구 진출 열쇠… 전반기 승률 5할 '사수' ‣ '4연승→6연패' 짧게 끝난 키움 반등 ‣ 손흥민, 유로파 결승전에서 프로 첫 우승 맛 볼까 ‣ MLB 다저스 김혜성 1안타·1타점…볼넷 1개 이정후에 판정승 ‣ '663일만의 투수 등판' 오타니, SD전 1이닝 1실점 ‣ 한국 남자배구, AVC 네이션스컵 첫 경기서 뉴질랜드 3-0 완파 ‣ 안세영 “더 두려운 존재가 되고 싶다”…다시 뛰는 韓배드민턴 출연: 정현호 PD(KBS) 김지한 기자(매일경제) 진행: 한상헌 아나운서

Welcome back to School Counseling Simplified! Summer Summit may be over, but the value continues. Today, I'm chatting with one of our incredible Summit speakers, Joyce Harduvel, about a topic every school counselor needs—sustainable self-care. If you missed the Summit, it's not too late! All the recordings and PD hours are still available when you join the IMPACT membership. You'll get access to this session and so much more. Joyce is a licensed clinical social worker. She is a passionate advocate for youth and the school counselors and social workers who support them. She worked in Chicago Public Schools for seven years, where she specialized in evidence-based and trauma-informed behavior intervention for students with chronic challenging behaviors. Joyce is an advocate for proactive professional self-care that allows school-based professionals to build the sustainable careers of their dreams so that they can do what is really important: support their students! She now works with school counselors and social workers as a coach and clinical supervisor while pursuing a law degree to further her skills in championing youth. In this episode, we talk about: How to create proactive, sustainable self-care routines Why burnout is a systems issue, not a personal failure Simple ways to make your workspace more peaceful for you and your students The power of building a support system at work and at home What it means to reconnect with your "why"   Joyce shares what a typical day looks like for her now: Seeing 2–3 private practice clients (individuals, couples, kids) Attending clinical supervision sessions with small counselor/social worker groups Reading (a lot!) for law school—she recommends Speechify for educators to save time Intentional self-care moments like unplugged lunch breaks, short naps, and reading for pleasure Her routine emphasizes boundaries, rest, and balance, something we can all learn from.   Joyce's biggest tip: Don't wait to start taking care of yourself. Create a proactive self-care plan now, not once you hit burnout Give yourself grace and go slow; this work is a marathon, not a sprint Set boundaries around your time and energy (especially your lunch break!) Remember: You don't need to do everything all at once Connect with others who “get it” and lean on your community As Joyce puts it, "If you want to stay in schools, I want to help you stay in schools and make it sustainable."   Don't miss out! Want access to this session and more? Join the IMPACT membership to get all Summer Summit replays, monthly PD trainings, downloadable resources, and a community of fellow school counselors.   Resources Mentioned:   Join IMPACT   Connect with Rachel: TpT Store Blog Instagram Facebook Page Facebook Group Pinterest Youtube Connect with Joyce: Instagram  www.joyce-lcsw.com   More About School Counseling Simplified: School Counseling Simplified is a podcast offering easy to implement strategies for busy school counselors. The host, Rachel Davis from Bright Futures Counseling, shares tips and tricks she has learned from her years of experience as a school counselor both in the US and at an international school in Costa Rica. You can listen to School Counseling Simplified on Apple Podcasts, Spotify, Google Podcasts, and more!  

In this episode, I'm joined by Sherri Sinclair—an incredible instructional coach, author, and thought partner. Together, we dive into the heart of what great teaching looks like.Sherri brings deep wisdom from her new book, Intentional Instructional Moves, and we talk about what really makes an impact in the classroom: strong classroom management, authentic student engagement, and meaningful assessment for learning. What stands out in Sherri's approach is how practical and intentional it is—from purposeful group work to clear, focused direct instruction to differentiation that actually works for real classrooms.We also dig into why clarity, connection, and continuous feedback are so essential—not just for student success, but for building learning environments where both teachers and students thrive.If you're a coach, a school leader, or a classroom teacher, you'll walk away from this conversation with real, usable strategies you can start trying tomorrow. Intentionality isn't just a theory—it's a practice. And Sherri shows us how to do it well.Thank you for being a part of our community.Feedback: We love hearing from you! Leave us a rating or comment to let us know what you think.Stay Connected: Follow our podcast for more episodes packed with insights and inspiration.Learn more about PD for Leaders:www.instructionalcoaching.com Learn more about the Instructional Coaching Planner:https://shorturl.at/XC1fq

BUFFALO, NY - June 17, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 10, 2025, titled “Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence.” The study, led by first author Kavin Sugumar and corresponding author Jordan M. Winter, from University Hospitals Seidman Cancer Center, reports on a rare group of pancreatic cancer (PC) patients who responded remarkably well to immunotherapy, a treatment typically considered ineffective for this cancer type. The analysis, which includes data from 14 patients across multiple U.S. institutions, identifies outcomes that could help refine treatment strategies for one of the most aggressive and deadly forms of cancer. “Between 2020–21, 471 oncologists from 91 major cancer centers in the United States were contacted.” Pancreatic cancer has among the lowest survival rates and few effective therapies. While immunotherapy has transformed the treatment landscape for several other cancers, it generally offers little benefit for pancreatic cancer. However, this study highlights a small but important group of patients who experienced significant and sustained responses to immune-based treatment without chemotherapy. Most had advanced or metastatic disease and had already progressed after standard treatments. Among the 14 patients, 82% had partial tumor shrinkage, and nearly one-third had a notable decrease in tumor markers. The median progression-free survival was 12 months, and most patients were still alive at follow-up, with survival rates of 80% at one year and 70% at two years. These outcomes contrast sharply with standard therapies, which often provide only a few months of benefit for similar patients. Interestingly, while some patients had high microsatellite instability (MSI-high)—a known marker for immunotherapy success—more than half did not, suggesting other biological mechanisms may be involved. This result highlights the need for new biomarkers to be discovered to predict treatment response in future studies. This case series is the largest focused exclusively on exceptional immunotherapy responders in pancreatic cancer. By excluding patients who received chemotherapy, the study isolates the effects of immune-based drugs, including PD-1 inhibitors such as pembrolizumab and nivolumab, CTLA-4 inhibitors like ipilimumab, and agents targeting macrophages. While the sample size is small, the findings challenge the assumption that immunotherapy is ineffective for nearly all pancreatic cancer patients. The study suggests that, under certain biological conditions, this treatment can be remarkably successful. Further research is needed to understand the underlying mechanisms. This work supports the need to reconsider how clinical trials are designed for pancreatic cancer and who is eligible for immunotherapy. Broader criteria and more personalized molecular profiling could help uncover hidden opportunities for treatment in this highly lethal cancer. DOI - https://doi.org/10.18632/oncotarget.28739 Correspondence to - Jordan M. Winter - jordan.winter@UHHospitals.org Video short - https://www.youtube.com/watch?v=VeWTcuVmqgM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28739 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

바이올린 연주에 작곡, 재즈 가수, 예능인, 그리고 복싱까지! 이렇게 다 잘하는 건 '반칙 아닌가요? 커튼콜 269회에서는 최근 TV 예능에서 일상을 공개하며 대중에게 친숙해진 바이올리니스트 대니 구와 함께 합니다. 실내악 연주에서 핑크퐁 '대니쌤', 재즈 보컬 활동, 최근의 TV 예능까지, 정해진 '틀'이 없는 그의 음악 인생 이야기 들어봅니다. "공부하고 오지 마세요. 그냥 오세요. 즐겁게 해드릴게요!" 클래식 음악계 '반칙왕' 혹은 '흥 부자' 대니 구가 들려주는 클래식 음악의 매력에 빠져보세요. ♬ 앙상블 디토 시즌 10 대니 구의 인사영상 ♬ 코른골드, 바이올린과 피아노를 위한 헛소동 모음곡 3번 - 대니 구 (Vn), 원재연 (Pf) ♬ 오늘 볼까요 - 대니 구&제이슨 리 ♬ I Fall in Love Too Easily - 대니 구 사진 및 영상 출처 : 대니 구 인스타그램, crediatv, 크클클TV, 8BallTown, Warner Classics Korea 음원 제공 : 대니 구 유튜브 재생목록 '김수현 문화전문기자의 커튼콜'을 추가해 보세요. https://han.gl/3YIq8 진행: SBS 김수현 문화전문기자, 이병희 아나운서 l 출연: 바이올리니스트 대니 구 l 글·편집 : 김은혜 PD

Today we're diving straight into your Instagram questions—always one of our favorite episodes! We kick things off with fitness talk, but you know us... what's a Q&A without getting a little off track?Join us as we break down everything from water weight and stress to the most embarrassing songs on our gym playlists, the TED talks we have absolutely no business giving, and so much more!If YOU'RE ready to make real, sustainable change in your life, jump on a free call with us - ⁠https://physiquedevelopment.typeform.com/to/ToP9TYLEAs always, it is our goal not only to supply you, the listener, with valuable insights on the topics or questions but also to plant some seeds for further research and thought. Be sure to like and subscribe and leave us a review if you loved this episode!Timestamps:(0:00) Today's topic(0:40) What is the difference between water weight, fat loss, & inflammation?(8:10) I'm doing everything right but not losing weight—what could be going on?(13:18) What's more important for physique change: volume or intensity?(22:51) How do I know if my stress is affecting my fat loss or progress?(24:35) What makes working with a coach different than just following a plan or app?(30:17) How do I know if I'm ready for coaching or just need more discipline?(31:41) Your gym playlist gets leaked to the world. What song are you most embarrassed to have on there?(32:32) What is the worst hobby your future child could pick up?(36:51) What's the most chaotic thing you've ever done out of pure boredom?(40:10) You get arrested—but your friends know it wasn't for something serious. What's the first thing they assume you did?(40:56) You're given a mic and told to give a TED Talk on something you have no business talking about—but you still commit 100%. What's your topic?(41:58) You get one free punch with no consequences. Who's it going to and why?(46:24) What's your Roman Empire—the thing you randomly think about way too often?(50:25) Wrap-upHave questions or comments for us? Submit them here - https://forms.gle/AEu5vMKNLDfmc24M7Check out our FREE 4-Week Glute Program - https://bit.ly/podcastglutesAnd keep the gains rolling with 12 MORE weeks of glute growth (use code POD at checkout for $25 off!) - https://train.physiquedevelopment.com/workout-plans/963551Follow us on Instagram:Coach Alex - https://www.instagram.com/alexbush__Coach Sue - https://www.instagram.com/suegainzPhysique Development - https://www.instagram.com/physiquedevelopment_Physique Development Podcast - https://www.instagram.com/physiquedevelopmentpodcastInquire to learn about nutrition-only coaching WITH exercise review - https://bit.ly/optimizeglutesInterested in the Physique Development Training Club App? Join here! - https://physiquedevelopment.appKeep up-to-date with all things PD, get exclusive content, snag freebies, and more by joining our email list! - https://dedicated-artist-6006.ck.page/emailsignupGrab a band tee here! - https://shopphysiquedevelopment.comLooking to hire the last coach you'll ever need? Apply here - https://physiquedevelopment.typeform.com/to/ToP9TYLEInterested in competition prep? Apply here - https://physiquedevelopment.typeform.com/to/Ii2UNAFor more videos, articles, and information, head to - https://physiquedevelopment.comIf you would like to support Physique Development and this podcast, please head over to your favorite podcast app and leave us a rating and review! This goes a long way in supporting this podcast and helps us continue to bring high-quality, honest content to you in the form of a podcast. Thank you for listening and we will see you all next time!----Produced by: David Margittai | In Post MediaWebsite: https://www.inpostmedia.comEmail: david@inpostmedia.com© 2025, Physique Development LLC. All rights reserved.

Michelle Moore is an EdTech expert turned mindset mentor and the creator of 100 Days to Self-Love, a transformative journal designed to help individuals reconnect with their worth and purpose. After years of leading in the education technology space, Michelle felt called to deepen her impact by guiding others through personal healing and growth. Blending her experience in education with her passion for mindfulness, energy alignment, and self-reflection, Michelle now supports others in living with intention, confidence, and joy. As a certified yoga instructor and advocate for self-care, she believes in the power of daily rituals to cultivate self-worth and unlock true potential.Her journal, 100 Days to Self-Love, reflects her mission to inspire others to embrace their authentic selves, align with their values, and live lives rooted in meaning and inner peace. 100% of the proceeds benefit Warrior Retreats where the idea for the journal was birthed. When she's not mentoring or creating tools for healing, Michelle enjoys traveling, laughing, and spending quality time with her two sons. 
Connect with her on Instagram @michellenmoore_
Grab your copy of 100 Days to Self-Love: https://a.co/d/9V8CJkD Check out these resources Michelle mentioned during our conversation.Passion project https://m.youtube.com/@thepassiontestforyouHuman design https://ahumandesign.com/Jillian on love https://podcasts.apple.com/us/podcast/jillian-on-love/id1640172049Journal link https://a.co/d/iqyzNP0Warrior retreats https://www.instagram.com/warriorretreats?igsh=NXoyMWs1bDFweGF1 ______________________________________________________________________ The Edupreneur: Your Blueprint To Jumpstart And Scale Your Education BusinessYou've spent years in the classroom, leading PD, designing curriculum, and transforming how students learn. Now, it's time to leverage that experience and build something for yourself. The Edupreneur isn't just another book—it's the playbook for educators who want to take their knowledge beyond the school walls and into a thriving business.I wrote this book because I've been where you are. I know what it's like to have the skills, the passion, and the drive but not know where to start. I break it all down—the mindset shifts, the business models, the pricing strategies, and the branding moves that will help you position yourself as a leader in this space.Inside, you'll learn how to:✅ Turn your expertise into income streams—without feeling like a sellout✅ Build a personal brand that commands respect (and top dollar)✅ Market your work in a way that feels natural and impactful✅ Navigate the business side of edupreneurship, from pricing to partnershipsWhether you want to consult, create courses, write books, or launch a podcast, this book will help you get there. Stop waiting for permission. Start building your own table.

This edWeb podcast is sponsored by Sched.The webinar recording can be accessed here.Teachers supported. Students succeeding. Communities thriving.In times of rapid change, teachers need ongoing learning and support more than ever so that students succeed. Join us for a practical, interactive edWeb podcast packed with proven strategies from experts at leading schools across the U.S. This is a “roll-your-sleeves-up” session, so bring your questions—we tackle them together, ensuring your PD sessions make a real difference.Learn best-practice tips for:Personalization and engagement: How to tailor sessions to individual needs, experience levels, and subject areas so teachers maximize professional growthPeer collaboration: How to promote open exchange of ideas, foster professional relationships, and create supportive learning environments where all voices are heardTaming logistics before, during, and after: Tips for a smooth experience with registration, check-ins, and sessions, and how to collect data to learn from each event and create better outcomes in future eventsYear-round professional development strategies: Ideas for a calendar of complementary professional development events around the year that keep learning fresh, timely, and comprehensiveThis session is ideal for district, school, and classroom leaders of all grade levels who are committed to empowering educators through best-practice professional development year-round. Listen to this edWeb podcast to transform your PD days and enhance student success!SchedLighten your workload with the all-in-one event platform for educatorsDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Learn more about viewing live edWeb presentations and on-demand recordings, earning CE certificates, and using accessibility features.

This episode join Goose and Maverick from California. We discuss the climate of policing in California, specifically in reference to a recent OIS in California. We do some news, is the new tread going to be PD's cracking down on memes? And so much morePlease patronize and support the LEO businesses that made this podcast possible.Sunday podcasts are brought to you by my friends over at OfficerPrivacy.com OfficerPrivacy has software that allows you to quickly remove your personal information from the internet. Use their software FREE for 14 days. Or their team of LEO's will remove your info for you. Sign up and feel safe again.How are First Responders hitting huge fitness / body/ health goals? Don't miss this one! Fit Responder Fit Responder is the top remote coaching program for first responders around the US. Having support that understands the demands and stressors of the job helps when you need an effective and realistic action plan to make your goals reality  Follow FIT RESPONDER for tips, guides, memes, etc. https://fitresponder.com/ Frontline Optics is a First Responder owned and operated sunglasses company based out of San DiegoThey offer Polarized UV400 sunglasses backed by a “No Questions Asked” Replacement Program. In addition, a portion of all sales directly benefits the First Responders Children's Foundation supporting the families of our Brothers and Sisters who made the ultimate sacrifice in service to their communities. Try them risk free with free shipping and 30 day free returns or exchanges.Wear them on or off duty, beat them up, hit them up, get a new pair!⁠⁠https://frontline-optics.com/discount/PMPM15⁠⁠PMPM coins - www.ghostpatch.comPMPM Merch - https://poorly-made-police-memes.creator-spring.com/?https://linktr.ee/Poorlymadepolicememes⁠⁠⁠⁠https://www.paypal.com/ncp/payment/4MYCYDRPX8ZU4⁠⁠⁠⁠https://www.thethinlinerockstation.com/

최다은PD의 첫 책 [비효율의 사랑: 소란한 세상에서 조용히 귀기울이기]를 선물로 드려요. 이벤트 공지 잘 들어주시고요, 자세한 내용은 인스타그램 참고 부탁드립니다.

This document records the presentment hearing for Sean Combs (also known by various aliases including Puff Daddy, P. Diddy, Diddy, PD, and Love) held on September 17, 2024, at 2:30 p.m. in the Southern District of New York before U.S. Magistrate Judge Robyn F. Tarnofsky. The case is formally docketed as United States v. Combs, 24 Cr. 542 (RFT). The presentment marked Combs' initial appearance in federal court following the unsealing of the indictment charging him with racketeering conspiracy and related offenses.During this proceeding, the Court advised Combs of the charges against him and the potential penalties, ensured that he was represented by counsel, and addressed matters related to bail and pretrial conditions. The hearing served as the procedural starting point for the federal criminal case, officially bringing Combs under the jurisdiction of the Court. No substantive arguments or evidence were presented at this stage; the focus remained on formal advisement and setting the framework for future proceedings.to contact me:bobbycapucci@protonmail.comsource:O9HLComC

This document records the presentment hearing for Sean Combs (also known by various aliases including Puff Daddy, P. Diddy, Diddy, PD, and Love) held on September 17, 2024, at 2:30 p.m. in the Southern District of New York before U.S. Magistrate Judge Robyn F. Tarnofsky. The case is formally docketed as United States v. Combs, 24 Cr. 542 (RFT). The presentment marked Combs' initial appearance in federal court following the unsealing of the indictment charging him with racketeering conspiracy and related offenses.During this proceeding, the Court advised Combs of the charges against him and the potential penalties, ensured that he was represented by counsel, and addressed matters related to bail and pretrial conditions. The hearing served as the procedural starting point for the federal criminal case, officially bringing Combs under the jurisdiction of the Court. No substantive arguments or evidence were presented at this stage; the focus remained on formal advisement and setting the framework for future proceedings.to contact me:bobbycapucci@protonmail.comsource:O9HLComC

This document records the presentment hearing for Sean Combs (also known by various aliases including Puff Daddy, P. Diddy, Diddy, PD, and Love) held on September 17, 2024, at 2:30 p.m. in the Southern District of New York before U.S. Magistrate Judge Robyn F. Tarnofsky. The case is formally docketed as United States v. Combs, 24 Cr. 542 (RFT). The presentment marked Combs' initial appearance in federal court following the unsealing of the indictment charging him with racketeering conspiracy and related offenses.During this proceeding, the Court advised Combs of the charges against him and the potential penalties, ensured that he was represented by counsel, and addressed matters related to bail and pretrial conditions. The hearing served as the procedural starting point for the federal criminal case, officially bringing Combs under the jurisdiction of the Court. No substantive arguments or evidence were presented at this stage; the focus remained on formal advisement and setting the framework for future proceedings.to contact me:bobbycapucci@protonmail.comsource:O9HLComCBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

Anchor Chat #19: Dangerous AssumptionsIn this episode, Dr. Woods discusses why dangerous assumptions lead to confusion, frustration, and missed opportunities. In this quick episode, he shares why it's essential to build context, check for understanding, and offer shared reference points—whether you're teaching a lesson, leading a meeting, or calling home. 

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Bemdaneprocel and the Future of Cell Therapy in Parkinson Disease" Rajesh Pahwa, MD, director of the Parkinson's Disease and Movement Disorder Center at the University of Kansas Medical Center, discusses the phase 3 exPDite-2 trial evaluating bemdaneprocel, an investigational cell therapy for Parkinson disease (PD). Pahwa explains the rationale behind cell replacement therapy as a means to restore dopamine production, outlining the progression from fetal tissue implants to stem cell–derived dopaminergic neurons. He details key elements of the study design, including patient selection criteria, trial endpoints, and long-term goals. Reflecting on decades of research in this space, he emphasizes the potential impact of a one-time, hardware-free surgical option and how this novel approach could complement or shift the current treatment landscape. While many questions remain, Pahwa highlights the promise of bemdaneprocel as a next-generation option in Parkinson care. Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page. Episode Breakdown: 1:00 – Mechanism and rationale behind bemdaneprocel as a dopaminergic cell therapy 3:00– Key design considerations for conducting a registrational phase 3 cell therapy trial 5:25 – Trial structure, eligibility criteria, and ongoing patient recruitment 6:35 – Neurology News Minute 8:45 – Significance of reaching phase 3 with a cell therapy in Parkinson disease 10:20 – Future role of cell therapy within the Parkinson disease treatment landscape 12:10 – Unique aspects of the exPDite-2 trial and what sets it apart from earlier efforts The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: BTK Inhibitor Fenebrutinib Demonstrates Long-Term Suppression of MS Activity in Open-Label Extension REGENXBIO Reports Positive Phase 1/2 Data for Higher Dose of RGX-202 in Duchenne Muscular Dystrophy NewAmsterdam Pharma Reports Positive Topline Data of Alzheimer Agent Obicetrapib from Phase 3 BROADWAY Trial Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Sue returns with Episode 5 of The Quiet Shift, sharing an episode she almost kept to herself. Despite weeks of staying consistent, being patient, and making adjustments, the scale refused to move.Join her as she talks about embracing discomfort and learning to create a safe space for your body to respond.As always, it is our goal not only to supply you, the listener, with valuable insights on the topics or questions but also to plant some seeds for further research and thought. Be sure to like and subscribe and leave us a review if you loved this episode!If YOU'RE ready to make real, sustainable change in your life, jump on a free call with us - ⁠https://physiquedevelopment.typeform.com/to/ToP9TYLEPrevious Quiet Shift Episodes:Why I'm Doing This (The Quiet Shift Begins) (Ep.1) - https://pod.fo/e/2d5c1dStarting Small—Because I Had To (Ep.2) - https://pod.fo/e/2d8f65What I Learned From My First Adjustments (Ep.3) - https://pod.fo/e/2dc082Sleep Was the Silent Saboteur (Ep.4) - https://pod.fo/e/2dfdb4Follow The Quiet Shift on Instagram:Episode 1 - https://www.instagram.com/p/DH3g_0YR1WKEpisode 2 - https://www.instagram.com/p/DIJQ6HNx29REpisode 3 - https://www.instagram.com/p/DIg4DvNt0GdEpisode 4 - https://www.instagram.com/p/DIw6WZmNGvbEpisode 5 - https://www.instagram.com/p/DJHLgSWNZ5KEpisode 6 - https://www.instagram.com/p/DJsPcpSPbApEpisode 7 - https://www.instagram.com/p/DKZ0M5ItGC1Connect with Coach Sue & Team PD:Coach Sue: https://www.instagram.com/suegainzPhysique Development: https://www.instagram.com/physiquedevelopment_Physique Development Podcast: https://www.instagram.com/physiquedevelopmentpodcastInquire to work with Team PD: https://physiquedevelopment.typeform.com/to/ToP9TYLEHave questions or comments for us? Submit them here - https://forms.gle/AEu5vMKNLDfmc24M7Check out our FREE 4-Week Glute Program - https://bit.ly/podcastglutesAnd keep the gains rolling with 12 MORE weeks of glute growth (use code POD at checkout for $25 off!) - https://train.physiquedevelopment.com/workout-plans/963551Keep up to date with all things PD, get exclusive content, snag freebies, and more by joining our email list! - https://dedicated-artist-6006.ck.page/emailsignupInterested in the Physique Development Training Club App? Join here! - https://physiquedevelopment.appInquire to learn about nutrition-only coaching WITH exercise review - https://bit.ly/optimizeglutesGrab a band tee here! - https://shopphysiquedevelopment.comLooking to hire the last coach you'll ever need? Apply here - https://physiquedevelopment.typeform.com/to/ToP9TYLEInterested in competition prep? Apply here - https://physiquedevelopment.typeform.com/to/Ii2UNAFor more videos, articles, and information, head to - https://physiquedevelopment.comIf you would like to support Physique Development and this podcast, please head over to your favorite podcast app and leave us a rating and review! This goes a long way in supporting this podcast and helps us continue to bring high-quality, honest content to you in the form of a podcast. Thank you for listening and we will see you all next time!----Produced by: David Margittai | In Post MediaWebsite: https://www.inpostmedia.comEmail: david@inpostmedia.com© 2025, Physique Development LLC. All rights reserved.

This document records the presentment hearing for Sean Combs (also known by various aliases including Puff Daddy, P. Diddy, Diddy, PD, and Love) held on September 17, 2024, at 2:30 p.m. in the Southern District of New York before U.S. Magistrate Judge Robyn F. Tarnofsky. The case is formally docketed as United States v. Combs, 24 Cr. 542 (RFT). The presentment marked Combs' initial appearance in federal court following the unsealing of the indictment charging him with racketeering conspiracy and related offenses.During this proceeding, the Court advised Combs of the charges against him and the potential penalties, ensured that he was represented by counsel, and addressed matters related to bail and pretrial conditions. The hearing served as the procedural starting point for the federal criminal case, officially bringing Combs under the jurisdiction of the Court. No substantive arguments or evidence were presented at this stage; the focus remained on formal advisement and setting the framework for future proceedings.to contact me:bobbycapucci@protonmail.comsource:O9HLComCBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

Throwback Thursday! Title: Leveraging Leadership featuring Dr. Robert ThornellOriginally Released On: 5-20-2022This week, we're revisiting one of our timeless episodes from Leading Out The Woods! In this episode:✅ Dr. Thornell shares the five distinct activities he believes all principals should exhibit. ✅ Dr. Thornell advocates for principals to “tell the story” about their school to generate buy-in and support for their staff and students.Whether you're hearing it for the first time or revisiting a classic, this conversation is packed with insights that still resonate today.

A team of responders enter a scene made safe(ish) by PD to find a very unhappy gunshot victim. Are they able to calm his rage and treat appropriately? Listen and find out!

This week on Counselor Chat, we're getting personal—and a little behind-the-scenes.

Summer break is here—but before you fill every day with appointments, activities, and professional development, let's pause. This episode is all about helping you find a better balance between rest, personal growth, boundaries, and just the right amount of planning.Whether you're someone who jumps directly into prep mode or someone who needs some solid nap time or lazy mornings (or both!), this episode will help you use your summer with intention—not obligation.In This Episode, You'll Learn:✅ Why true rest matters—and how to define what that looks like for you ✅ Ways to grow personally that have nothing to do with IEPs or PD hours ✅ How to set boundaries that protect your time (and your sanity) ✅ What a “Do Not Do” list is—and why you need one ✅ How to make peace with not doing all the things this summerMentioned in the Episode:

Not all PD is created equal—and if you've ever sat through a session on a math curriculum you don't teach, you already know that. In this episode, Bryson breaks down why content-specific professional development is a must for music teachers and how to start advocating for it in your district. He shares three key reasons why general PD often misses the mark for music educators and offers actionable steps for finding, requesting, and justifying music-focused learning—especially with the support of national organizations and case studies. Whether you're tired of irrelevant sessions or looking for ways to stay current and inspired, this episode will help you build the case for PD that actually speaks your language. Episode Chapters: 0:00 Introduction 3:01 3 Concrete Reasons Why Content-Specific PD Matters 6:04 How to Advocate Effectively 7:52 Where to Start Taking Action 9:10 Breaking Out of “Music Teacher Island” 11:22 Takeaways Links and Resources: Elementary Newbie Guide Disabilities Guide Steady Beat Survival Guide Join That Music Teacher Community The Elementary Music Summit® Have questions or want to share feedback? Reach out to us at hello@thatmusicteacher.com - we'd love to hear from you!

In this episode, PD sits down with Joe Latuszek, Immanuel's Praise Team Director. to unpack the dramatic shifts in music consumption, media trends, and cultural identity over the last two decades. From the shared soundtrack of the early 2000s to today's fragmented playlist culture, they explore how platforms like TikTok have reshaped music discovery and erased decade-defining sounds. The conversation dives into the generational divide fueled by fast-moving tech, evolving worship styles in church, and the search for authenticity in a curated world. Whether you're a pastor, a creator, or a culture watcher, this episode offers fresh insight into navigating the digital age with faith, wisdom, and discernment.

Welcome back to another episode of School Counseling Simplified! We're just TWO days away from Summer Summit, my virtual conference for school counselors happening June 11th and 12th! This two-day event is packed with amazing topics, live Q&A sessions, and even a virtual happy hour. For just $39, you'll get your seat at the summit plus your first month inside the IMPACT membership! Today I'm joined by Brandon Gernux (he/they), an elementary school counselor from Santa Ana, CA, and one of our Summer Summit speakers! Brandon brings such valuable insight into making Tier 1 classroom lessons more inclusive for all brains. He's passionate about bridging the gap between school counseling and neurodivergent disability, and today's conversation is all about practical ways to infuse anti-ableist, inclusive practices into your everyday counseling work. You'll hear us talk about: What neurodiversity means and how to talk about it with students Why Tier 1 supports matter and how they can create a more inclusive school culture Brandon's sensory exploration classroom lesson idea How to create sensory-safe spaces around your school Why you don't need to do everything at once as a new counselor, and what to focus on instead Brandon is beginning a PhD in Education with an emphasis on Disability Studies this fall, and he is truly a thoughtful and inspiring voice in the counseling space. You'll love hearing from him today and at Summer Summit! Don't miss out! Want access to hundreds of counseling resources, monthly exclusive trainings (with PD certificates), and a supportive community of school counselors? My IMPACT membership gives you all of that and your ticket to my fourth annual Summer Summit! Learn more and join today by clicking the link below!   Resources Mentioned: Summer Summit   Connect with Rachel: TpT Store Blog Instagram Facebook Page Facebook Group Pinterest Youtube Connect with Brandon: Instagram    More About School Counseling Simplified: School Counseling Simplified is a podcast offering easy to implement strategies for busy school counselors. The host, Rachel Davis from Bright Futures Counseling, shares tips and tricks she has learned from her years of experience as a school counselor both in the US and at an international school in Costa Rica. You can listen to School Counseling Simplified on Apple Podcasts, Spotify, Google Podcasts, and more!  

At 11 years old, Jared Hamilton was handed a Weight Watchers book and it shattered his relationship with food and self-confidence. Now, Jared has helped thousands unlearn those same behaviors he experienced.Listen in as he and Alex sit down and discuss the most acceptable adult eating disorder and how he changed his behaviors over time. Jared shares his personal journey from childhood trauma to becoming a leading voice in the fitness industry, offering hope and actionable insights for anyone ready to break free from diet culture's grip and heal their relationship with food!If YOU'RE ready to make real, sustainable change in your life, jump on a free call with us - ⁠https://physiquedevelopment.typeform.com/to/ToP9TYLEAs always, it is our goal not only to supply you, the listener, with valuable insights on the topics or questions but also to plant some seeds for further research and thought. Be sure to like and subscribe and leave us a review if you loved this episode!Timestamps:(0:00) Introducing Jared Hamilton(1:08) Jared's history with negative self-image, food noise, & fad dieting(7:04) Navigating the shame & stigma around food & dietary choices(9:07) Why you can't be one way but teach another(12:56) You can't fix what you don't know(17:23) The process of unlearning disordered eating patterns(19:28) Rebuilding a healthy relationship with food (how to LITERALLY rewire your brain)(23:35) Making sure new habits stick(27:25) Establishing personal boundaries & improving communication(30:36) The pros and cons of GLP-1 use(35:21) The real danger of Weight Watchers (& other dieting systems)(43:01) Our evolution as coaches (what young us would think about us now)(46:39) Where you can find Jared onlineConnect with Jared:Instagram - https://www.instagram.com/realjaredhamiltonTikTok - https://www.tiktok.com/@realjaredhamiltonDieting From The Inside Out Podcast - https://podfollow.com/1349300090The Food Noise Solution - https://inquire.hamiltontrained.com/food-noiseHave questions or comments for us? Submit them here - https://forms.gle/AEu5vMKNLDfmc24M7Check out our FREE 4-Week Glute Program - https://bit.ly/podcastglutesAnd keep the gains rolling with 12 MORE weeks of glute growth (use code POD at checkout for $25 off!) - https://train.physiquedevelopment.com/workout-plans/963551Follow us on Instagram:Coach Alex - https://www.instagram.com/alexbush__Coach Sue - https://www.instagram.com/suegainzPhysique Development - https://www.instagram.com/physiquedevelopment_Physique Development Podcast - https://www.instagram.com/physiquedevelopmentpodcastInquire to learn about nutrition-only coaching WITH exercise review - https://bit.ly/optimizeglutesInterested in the Physique Development Training Club App? Join here! - https://physiquedevelopment.appKeep up-to-date with all things PD, get exclusive content, snag freebies, and more by joining our email list! - https://dedicated-artist-6006.ck.page/emailsignupGrab a band tee here! - https://shopphysiquedevelopment.comLooking to hire the last coach you'll ever need? Apply here - https://physiquedevelopment.typeform.com/to/ToP9TYLEInterested in competition prep? Apply here - https://physiquedevelopment.typeform.com/to/Ii2UNAFor more videos, articles, and information, head to - https://physiquedevelopment.comIf you would like to support Physique Development and this podcast, please head over to your favorite podcast app and leave us a rating and review! This goes a long way in supporting this podcast and helps us continue to bring high-quality, honest content to you in the form of a podcast. Thank you for listening and we will see you all next time!----Produced by: David Margittai | In Post MediaWebsite: https://www.inpostmedia.comEmail: david@inpostmedia.com© 2025, Physique Development LLC. All rights reserved.

Maria-Katarina Johannesson, a.k.a. Linksandmaria, likes to grow things - both businesses and plants. Specializing in link building, digital PR, and making brands stand out, she's all about building relationships while keeping the sales perspective front and center.Website: https://linksandmaria.com/  ______________________________________________________________________ The Edupreneur: Your Blueprint To Jumpstart And Scale Your Education BusinessYou've spent years in the classroom, leading PD, designing curriculum, and transforming how students learn. Now, it's time to leverage that experience and build something for yourself. The Edupreneur isn't just another book—it's the playbook for educators who want to take their knowledge beyond the school walls and into a thriving business.I wrote this book because I've been where you are. I know what it's like to have the skills, the passion, and the drive but not know where to start. I break it all down—the mindset shifts, the business models, the pricing strategies, and the branding moves that will help you position yourself as a leader in this space.Inside, you'll learn how to:✅ Turn your expertise into income streams—without feeling like a sellout✅ Build a personal brand that commands respect (and top dollar)✅ Market your work in a way that feels natural and impactful✅ Navigate the business side of edupreneurship, from pricing to partnershipsWhether you want to consult, create courses, write books, or launch a podcast, this book will help you get there. Stop waiting for permission. Start building your own table.